Innovator firms have deployed several tactics to derail uptake of biosimilars in the US, including whisper campaigns that allege such drugs are inferior to interchangeable products and their original
Innovator firms have deployed several tactics to derail uptake of biosimilars in the US, including whisper campaigns that allege such drugs are inferior to interchangeable products and their original
Scott Smith , Celgene Corp. ’s president and chief operating officer, is leaving the company, effective immediately. His abrupt departure follows a series of product setbacks for the firm, and his m
Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals. In an interview with